Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience

Table 4

Baseline and end-treatment SUV max values recorder for all patients in the main lesion assessed by  ⁶⁸Ga-peptide PET/CT tabulated on the basis of patients’ functional response.

	Main lesion
	Baseline SUV max value			End-treatment SUV max value
Functional response	Mean	Median	Range	Mean	Median	Range
CR	45.3	45.3	—	0.9	0.9	—
PR	79.7	29.2	6.3–119.9	39.2	17.8	3.2–49.1
SD	31.1	20.9	6.6–82.0	31.2	28.2	11.2–61.3
PD^ç	27.9	22	11.7–55.8	35.7	26	15.7–74.7

^çData from the 4 patients in which PD was assessed using  ⁶⁸Ga-peptide PET/CT.